Jubilant HollisterStier LLC (JHS) — a wholly owned subsidiary of Jubilant Pharmova and a leading North American contract manufacturer specialising in sterile injectables — has launched a new Sterile Fill & Finish line, its third at the Spokane manufacturing facility in Washington, USA.

The milestone was marked by the successful production of the first commercial batch, officially initiating revenue generation from the new line. This development represents a major step forward in JHS’s multi-phase expansion strategy and increases the Spokane facility’s manufacturing capacity by 50 percent.

Developed with an investment of USD 132 million, the new line features an advanced isolator technology designed to deliver enhanced sterility assurance, throughput and operational precision. Built to meet the most stringent global regulatory standards, it strengthens JHS’s capability to support complex injectable programmes across diverse therapeutic areas.

With the upcoming commissioning of its fourth line, JHS is on track to double its total sterile injectable manufacturing capacity at the Spokane site.

Commenting on the development, Chris Preti, CEO - CDMO Sterile Injectables, said, “Launching our Third Line is more than a milestone for us—it’s a defining moment in Jubilant HollisterStier’s journey. This expansion also reflects our deep-rooted commitment to continued growth, technological excellence and the community at Spokane.”  

“With Third Line now operational and Fourth Line on the horizon, we are not just doubling our capacity, we’re building a future that will create hundreds of new jobs, strengthen the US pharmaceutical supply chain and reaffirm our role as a trusted partner in delivering life-saving therapies to patients around the world,” he added.

The company expects to reach the full utilisation for the new line in the next three years.